Randomized Phase II Study of Docetaxel plus Bevacizumab or Pemetrexed plus Bevacizumab for Elderly Non-Squamous NSCLC (TORG1323)

被引：0

作者：

Kozuki, Toshiyuki ^{[1
]}

Nogami, Naoyuki ^{[1
]}

Yamashita, Natsumi ^{[2
]}

Shinkai, Tetsu ^{[3
]}

Shukuya, Takehito ^{[4
,5
]}

Seki, Nobuhiko ^{[6
]}

Kato, Terufumi ^{[7
]}

Satouchi, Miyako ^{[8
]}

Masuda, Noriyuki ^{[9
]}

Watanabe, Koshiro ^{[10
]}

机构：

[1] Natl Hosp Org, Shikoku Canc Ctr, Dept Thorac Oncol & Med, Matsuyama, Ehime, Japan

[2] Natl Hosp Org, Shikoku Canc Ctr, Clin Res Ctr, Matsuyama, Ehime, Japan

[3] Shonan East Gen Hosp, Dept Internal Med, Chigasaki, Kanagawa, Japan

[4] Juntendo Univ, Fac Med, Div Resp Med, Tokyo, Japan

[5] Grad Sch Med, Tokyo, Japan

[6] Teikyo Univ, Sch Med, Dept Med Oncol, Tokyo 173, Japan

[7] Kanagawa Cardiovasc & Resp Ctr, Resp Med, Yokohama, Kanagawa, Japan

[8] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo, Japan

[9] Kitasato Univ, Sch Med, Dept Resp Med, Kanagawa, Japan

[10] Thorac Oncol Res Grp, Yokohama, Kanagawa, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期

关键词：

elderly; Clinical Trial in Progress; NSCLC; bevacizumab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.01-085

引用

页码：S666 / S666

页数：1

共 50 条

[1] Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly pts with Untreated Advanced NSCLC: TORG1323
Ito, K.
Hataji, O.
Tanzawa, S.
Harada, T.
Fujimoto, N.
Bessho, A.
Takamura, K.
Takahashi, K.
Shinkai, T.
Kozuki, T.
Satouchi, M.
Kato, T.
Seki, N.
Shukuya, T.
Yamashita, N.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S475 - S476
[2] Open-label multicenter randomized phase II study of docetaxel plus bevacizumab or pemetrexed plus bevacizumab for elderly (≥75 years old) patients (pts) with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC): TORG1323
Honda, T.
Kouzuki, T.
Tsunezuka, Y.
Seki, N.
Shibayama, T.
Okimoto, T.
Taniguchi, H.
Takeda, Y.
Hata, N.
Sugimoto, K.
Takahashi, N.
Sakai, K.
Nishimura, T.
Ikeda, S.
Watanabe, S.
Mori, K.
Shinkai, T.
ANNALS OF ONCOLOGY, 2018, 29 : 506 - 506
[3] Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323
Kozuki, Toshiyuki
Nogami, Naoyuki
Hataji, Osamu
Tsunezuka, Yoshio
Seki, Nobuhiko
Harada, Toshiyuki
Fujimoto, Nobukazu
Bessho, Akihiro
Takamura, Kei
Takahashi, Kazuhisa
Satouchi, Miyako
Kato, Terufumi
Shukuya, Takehito
Yamashita, Natsumi
Okamoto, Hiroaki
Shinkai, Tetsu
TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (03) : 459 - +
[4] A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer
Yoshida, Hironori
Kim, Young Hak
Sakamori, Yuichi
Nagai, Hiroki
Ozasa, Hiroaki
Kaneda, Toshihiko
Yoshioka, Hiroshige
Nakagawa, Hiroaki
Tomii, Keisuke
Okada, Asuka
Yoshimura, Kenichi
Hirabayashi, Masataka
Hirai, Toyohiro
ANTICANCER RESEARCH, 2020, 40 (05) : 2981 - 2987
[5] Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321
Kasai, Takashi
Mori, Kiyoshi
Nakamura, Yoichi
Seki, Nobuhiko
Ichikawa, Yasuko
Saito, Haruhiro
Kondo, Tetsuro
Nishikawa, Kazuo
Otsu, Satoshi
Bessho, Akihiro
Tanaka, Hiroshi
Yamaguchi, Hiroyuki
Kaburagi, Takayuki
Imai, Hisao
Mori, Keita
Ohtake, Junya
Okamoto, Hiroaki
CANCER MEDICINE, 2023, 12 (14): : 14988 - 14999
[6] Phase II Study of S-1 plus Bevacizumab for Pretreated Patients with Non-Squamous NSCLC
Yamada, Kazuhiko
Ichiki, Masao
Takahashi, Kazuhisa
Hisamatsu, Yasushi
Azuma, Koichi
Tokito, Takaaki
Ishii, Hidenobu
Takeoka, Hiroaki
Shukuya, Takehito
Nishikawa, Kazuo
Hoshino, Tomoaki
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S661 - S661
[7] PII of Pemetrexed or Pemetrexed Plus Bevacizumab for Previously Untreated Elderly (>=75) Non-Squamous NSCLC (LOGIK1201)
Maruyama, R.
Fukuda, M.
Kitazaki, T.
Ogawara, D.
Ichiki, M.
Mukae, H.
Nakagaki, N.
Kishimoto, J.
Ichinose, Y.
Sugio, K.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S486 - S487
[8] Randomized phase II study comparing cisplatin plus pemetrexed plus bevacizumab with carboplatin plus paclitaxel plus bevacizumab in treatment-naive advanced non-squamous non-small cell lung cancer (CLEAR study)
Koyama, R.
Udagawa, H.
Sugiyama, E.
Komuta, K.
Mori, M.
Yokoyama, T.
Sasaki, T.
Saito, H.
Ishida, H.
Nakagawa, H.
Sekine, A.
Tamura, A.
Shingyoji, M.
Mizuno, K.
Nakamura, A.
Kinoshita, A.
Yamanaka, T.
Goto, K.
ANNALS OF ONCOLOGY, 2018, 29
[9] A Phase II Study of Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed in Elderly Patients with Advanced Non-Squamous NSCLC
Tamiya, Motohiro
Tamiya, Akihiro
Kaneda, Hiroyasu
Nakagawa, Kazuhiko
Goto, Koichi
Yoh, Kiyotaka
Okamoto, Hiroaki
Shimokawa, Tsuneo
Tanaka, Hiroshi
Abe, Tetsuya
Daga, Haruko
Takeda, Koji
Hirashima, Tomonori
Atagi, Shinji
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S316 - S316
[10] Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
Yokoi, Takashi
Torii, Yoshitaro
Katashiba, Yuichi
Sugimoto, Hiroyuki
Tanijiri, Tsutomu
Ogata, Makoto
Inagaki, Noriko
Kibata, Kayoko
Hayashi, Mina
Niki, Maiko
Shimizu, Toshiki
Miyara, Takayuki
Kurata, Takayasu
Nomura, Shosaku
ONCOLOGY LETTERS, 2014, 8 (06) : 2453 - 2457

← 1 2 3 4 5 →